6/13/2012 10:05:23 AM
SAN ANTONIO--(BUSINESS WIRE)--Azaya Therapeutics, Inc. announced final results from the Phase I study of its anti-cancer drug, ATI-1123 (liposomal docetaxel), today. The results showed that 79 percent of heavily pretreated patients received benefit from ATI-1123. The 29 patients enrolled in the study suffered from a variety of solid tumors, including cervical, gastric, melanoma, non-small cell lung (NSCLD), ovarian, pancreatic, prostate, thyroid, urachal and uterine cancers.
comments powered by